Where we are in treat to target era? Predictive factors for remission and drug switching in patients with axial spondyloarthritis: a real-life evidence from BioStaR nationwide registry

Bodur, Hatice; Yurdakul, Fatma; ATAMAN, ŞEBNEM; Cay, Hasan; GÜRER, GÜLCAN; ÇAPKIN, ERHAN; SEZER, İLHAN; DURUÖZ, MEHMET; ALKAN MELİKOĞLU, Meltem; Rezvani, Aylin; YAĞCI, İLKER; GÖĞÜŞ, FERİDE; KAMANLI, AYHAN; AKGÜL, ÖZGÜR; ÇEVİK, REMZİ

doi:10.1007/s10067-022-06145-8

Where we are in treat to target era? Predictive factors for remission and drug switching in patients with axial spondyloarthritis: a real-life evidence from BioStaR nationwide registry

Bodur H., Yurdakul F. G., ATAMAN Ş., Cay H. F., GÜRER G., ÇAPKIN E., ...More

CLINICAL RHEUMATOLOGY, vol.41, no.7, pp.2053-2063, 2022 (SCI-Expanded, Scopus)

Publication Type: Article / Article
Volume: 41 Issue: 7
Publication Date: 2022
Doi Number: 10.1007/s10067-022-06145-8
Journal Name: CLINICAL RHEUMATOLOGY
Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, CAB Abstracts, EMBASE, MEDLINE, Veterinary Science Database
Page Numbers: pp.2053-2063
Keywords: Disease modifying anti rheumatic drugs, Drug switching, Remission induction, Spondyloarthritis, ANKYLOSING-SPONDYLITIS, DISEASE-ACTIVITY, INHIBITORS, THERAPY, HLA-B27
Ankara University Affiliated: Yes

Abstract

Objectives Factors associated with disease activity of axial spondyloarthritis (axSpA) and switching of biologic disease-modifying anti-rheumatic drugs have not been clearly defined. We aimed to evaluate clinical characteristics of patients with axSpA, factors related to remission in treat to target era and predictive factors for biologic disease-modifying anti-rheumatic drug switching.